What Are Medications for PKU?
The first thing you should know when your child has phenylketonuria (PKU) is that medications have come a long way. Researchers are also working to improve them even more. It's a lifelong disease that you and your growing child will need to manage. But doctors no longer have to rely solely on a strict diet to keep your child from building up harmful levels of phenylalanine (phe).
Your options will be limited while your child is younger. But you'll have new options to look forward to as they get older. It's likely the number of treatments will continue to grow and improve in the future as new medicines in development and clinical trials get approved. But you can rest assured that PKU treatment advances have already made a big difference for the PKU community, says Hope Northrup, MD, director of the National Organization for Rare Disorders (NORD) Rare Disease Center of Excellence at UTHealth Houston.
A shift in focus
"For decades, I feel like we in the medical community failed our patients with PKU because we didn't really recognize that the prescribed diet, which is very low in natural protein, is virtually impossible to maintain over your lifetime," Northrup says.
The traditional PKU diet restricts protein to about 5 grams per day, she says, when a person without PKU normally eats 80 to 100 grams of protein per day. As a result, Northrup says a PKU diet is often loaded with unhealthy amounts of fat and sugar. The diet also requires a metabolic formula to supplement all the other amino acids you'd be missing with a diet so low in protein. While the PKU diet protects the brain, the realization in the early 2000s that it wasn't enough led to successful efforts to advance PKU treatment and improve lives.
"It's really been a sea change, and I think a very important and helpful one for patients," Northrup says.
Learn more about medications for your child with PKU and their pros and cons.
What Is Sapropterin Dihydrochloride (Kuvan/Generic) for PKU?
Sapropterin is a medicine you take by mouth to help lower phenylalanine levels. The FDA approved it for PKU in 2007. It's also known as a synthetic BH4 cofactor.
How does it work?
Our bodies normally convert phenylalanine to tyrosine via an enzyme called phenylalanine hydroxylase (PAH). This essential process requires a cofactor called tetrahydrobiopterin, or BH4. When you have PKU, this metabolic conversion doesn't work the way it should. If your PAH enzyme has some activity, taking sapropterin can help to make it work better. As a result, the medicine may reduce your levels of phenylalanine.
"What we figured out was that, in some people, you could enhance the residual enzymatic activity they were producing and better utilize it if you gave them exogenous BH4," Northrup explains. "Your body has BH4 and recycles it, and you can make it, but we would give them more, and in 30% to 50% of people, they could have a little bit more protein than they were able to have before."
Who is it for?
Sapropterin is approved for babies as young as 1 month of age, but it mainly works for children and adults with milder forms of PKU.
What are the pros?
When your PAH enzyme still has some activity, this medicine can help it work better. It can help to lower phenylalanine levels by about 30%. This can make it possible to eat more protein safely than you otherwise could. Kids who respond to it can have a more flexible diet. It may help with growth and quality of life.
What are the cons?
Sapropterin doesn't work for everyone. The response likely depends on the specific gene variants causing your child's PKU. But it's not easy to predict responses. You may have to try it for about a month to see if it helps. Since it reduces phenylalanine levels only partially, even when it works, this medicine still requires a restricted PKU diet.
What Is Sepiapterin (Sephience) for PKU?
Sepiapterin is a powder you take by mouth. It's a natural precursor of the BH4 cofactor.
How does it work?
Taking sepiapterin can increase your child's BH4 cofactor levels and help to stabilize the PAH enzyme. As a result, it can help to lower phenylalanine levels.
Who is it for?
The FDA approved sepiapterin in July 2025 for kids and adults. Infants as young as 1 month of age can use it.
What are the pros?
Clinical trial results of sepiapterin showed 84% of people treated with this medicine had reduced blood levels of phenylalanine. Unlike sapropterin, it works for about 7 in every 10 people with classic PKU. Most people taking it can include more protein in their diets.
What are the cons?
Sepiapterin still doesn't work for everyone. The only way to know if it works for you or your child is to try it with careful monitoring of your diet and nutrition. You have to avoid certain other medicines while taking sepiapterin. It also may come with side effects including:
- Diarrhea
- Headache
- Belly pain
- Abnormally low phenylalanine levels (hypophenylalaninemia)
- Changes in the color of your stool
What Is Pegvaliase-pqpz (Palynziq) for PKU?
It's an injectable medicine for PKU that you take every day. The active ingredient is an enzyme called phenylalanine ammonia lyase (PAL). It's also known as enzyme substitution therapy.
How does it work?
The PAL enzyme converts phenylalanine into ammonia and a chemical compound called trans-cinnamic acid. While it doesn't work the same way the PAH enzyme does and doesn't replace the enzyme you're missing, it allows your body to get rid of excess phenylalanine in another way.
Who is it for?
The FDA approved pegvaliase-pqpz (Palynziq) in 2018 for adults ages 18 and up. In 2026, the approval was expanded to include adolescents as young as 12.
What are the pros?
This medicine works even if your PKU is severe. While it doesn't replace the missing PAH, it gives you another enzyme to break down phenylalanine. As a result, it's possible to eat a normal diet.
What are the cons?
"The problem with enzyme substitution therapy is it's highly immunogenic," Northrup says.
Not everyone can tolerate this medicine because of side effects, including hypersensitivity and anaphylaxis. To take it, you'll need careful monitoring to find the right dose and avoid an allergic reaction. More study is needed to know how well it works long term.
What Are Oral Small Molecules in the Pipeline for PKU?
Researchers and companies are working to develop new medicines for PKU that work in different ways. One that's especially promising is a new class of oral medicines targeting a phenylalanine transporter in the kidneys called SLC6A19. One promising medicine in this class is called repinatrabit (JNT-517).
How does it work?
When your blood is filtered through your kidneys, they take up amino acids, including phenylalanine, which goes back into the bloodstream, Northrup explains.
"This drug actually blocks the reuptake [of phenylalanine] at the level of the kidneys," she says.
Who is it for?
This medicine isn't yet approved, but phase 3 clinical trials are testing it in adults, ages 18 and up, with PKU.
What are the pros?
This medicine promises a new way to reduce phenylalanine levels for anyone with PKU. It might reduce phenylalanine with fewer side effects than enzyme substitution therapy. It also doesn't require daily injections.
What are the cons?
This medicine looks promising based on trial results so far, but it isn't available yet. It also isn't known how well it will reduce phenylalanine levels. For any new medicine, more long-term study is needed.
What Are Gene and mRNA Therapies for PKU?
Gene and messenger RNA (mRNA) therapies use DNA or mRNA to deliver working PAH enzymes that are missing in PKU.
How do they work?
In gene therapy, harmless viruses called adeno-associated virus (AAV) vectors send working PAH genes to cells in the liver. Early studies suggest it could work to boost PAH and reduce phenylalanine. mRNA therapies instead use lipid nanoparticles to send mRNA encoding the missing PAH enzymes into the liver. The idea is that these therapies could allow the liver to make working PAH without permanently inserting DNA.
Who are they for?
An early clinical trial is testing the safety of gene therapy in adults with PKU. But gene or mRNA therapy isn't currently available for PKU.
What are the pros?
Gene and mRNA therapies could be promising ways to treat PKU by restoring normal PAH function. They might work without requiring you to take daily medicine.
What are the cons?
As of 2026, these therapies are still experimental. There are questions about how to make them work best, how long they will work, and whether they will be safe in the long term. An mRNA medicine for PKU was in development, but the planned safety trial has since been withdrawn. So, it's not clear if development of mRNA therapies will move forward.
What Is the Outlook for PKU Medications and Treatment Approaches?
Northrup says it's important to remember that no two people with PKU are alike. PKU involves many different PAH genetic variants. Your child may respond differently to treatment than someone else based on their genes, differences in their diet, or other factors. You and your child may also have different preferences when it comes to treatment and the role of medications versus dietary changes.
In the future, it's likely the number of treatment options for PKU will grow. There may also be tools to measure the specific genes and PAH function in each individual and use that information to predict the best treatment option. To expand your options, ask your care team about any new treatment options or clinical trials that may be available.
"Every visit a PKU patient has with me, part of the visit is to review clinical trials and what is already FDA-approved so that they know," Northrup says. "They have information and they can make choices. It's very important to keep up with what's available."
Her message about the future for parents caring for a child with PKU is one full of hope. "We are improving," she says. "There are already drugs available. There are going to be more, and it's just going to keep getting better."
Show Sources
Photo Credit: Moment/Getty Images
SOURCES:
Hope Northrup, MD, director, National Organization for Rare Disorders (NORD) Rare Disease Center of Excellence, UTHealth Houston.
Mayo Clinic: "Sapropterin (oral route)."
StatPearls: "Phenylketonuria (PKU)."
ClinicalTrials.gov: "A Study of JNT-517 in Participants With Phenylketonuria (PKU)," "AAV Gene Therapy Study for Subjects with PKU," "A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria."
Journal of Inherited Metabolic Disease: "Personalized Genotype‐Based Approach for Treatment of Phenylketonuria."
